0000000000292733

AUTHOR

Ozan Anguen

showing 1 related works from this author

The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment

2014

TPS9113^ Background: Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma patients suggest improvement in disease-free survival (DFS), a metaanalysis could only show ...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomamedicine.medical_treatmentMedizinmedicine.diseaseOncologyInterferonInternal medicineToxicitymedicinebusinessneoplasmsAdjuvantmedicine.drug
researchProduct